Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antiviral
Biotech
Shionogi's RSV antiviral reduces viral load in ph. 2 adult trial
Shionogi’s respiratory syncytial virus antiviral for adults has proven its ability to reduce viral load in a phase 2 trial.
James Waldron
Jan 30, 2025 5:32am
AI drug discoverer's antiviral reduces COVID in mouse lungs
Jan 21, 2025 12:42am
Atea's COVID antiviral fails to halt hospitalizations in phase 3
Sep 13, 2024 10:10am
Free-floating bacterial gene challenges biology's cardinal rules
Aug 14, 2024 10:31am
A seventh known patient seems cured of HIV
Jul 18, 2024 1:59pm
Poseida makes case for safety of Roche-partnered nonviral CAR-T
Dec 10, 2023 12:00pm
